Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma [0.03%]
一线免疫检查点抑制剂联合化疗治疗肺肉瘤样癌疗效及安全性的评估
He Du,Xinyu Song,Fengying Wu
He Du
Background: Pulmonary sarcomatoid carcinoma (PSC) represents a rare subtype of non-small cell lung cancer (NSCLC), and it has poor pathologic differentiation, aggressive progression, and early metastasis. Conventional ant...
Clinical Trial
Lung Cancer (Auckland, N.Z.). 2025 Jun 9:16:73-83. DOI:10.2147/LCTT.S494990 2025
Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells [0.03%]
解析FASN在敏感和耐药EGFR突变非小细胞肺癌干细胞中的作用
Emma Polonio-Alcalá,Sira Ausellé-Bosch,Gerard Riesco-Llach et al.
Emma Polonio-Alcalá et al.
Introduction: Cancer stem cells (CSCs) drive tumor initiation, relapse, and metastasis. Our research team developed polycaprolactone electrospun (PCL-ES) scaffolds for enriching lung CSCs (LCSCs) since monolayer culture d...
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) [0.03%]
柳叶刀深度：III期LAURA研究——术后奥希替尼辅助治疗可切除IB至IIIA期EGFR突变NSCLC患者的疗效和安全性及FLAURA研究——奥希替尼对比对照组在不可手术的局部晚期或转移性表皮生长因子受体突变阳性非小细胞肺癌患者中的疗效和安全性
Faustine X Luo,Zhaohui Arter,Sai-Hong Ignatius Ou et al.
Faustine X Luo et al.
The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programm...
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study [0.03%]
越南早期非小细胞肺癌患者的EGFR突变流行率：EARLY-EGFR研究
Tu Van Dao,Van Luong Dinh,Thanh Vinh Doan et al.
Tu Van Dao et al.
Introduction: Comprehensive profiling of mutations in the EGFR gene is vital for selecting patients eligible for EGFR targeted therapies. Methods: ...
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer [0.03%]
表皮生长因子受体突变非小细胞肺癌转化成为小细胞肺癌后的后续治疗对其临床疗效的影响分析
Ching-Yi Chen,How-Wen Ko,Po-Wei Hu et al.
Ching-Yi Chen et al.
Purpose: In epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients treated with EGFR-tyrosine kinase inhibitors (TKIs), transformation to small-cell lung cancer (SCLC) is associated wit...
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC [0.03%]
AACR基因组信息学数据库中所有三类（I，II，III）BRAF突变（BRAF+）NSCLC的肿瘤突变负荷(TMB)综合调查
Zhaohui Liao Arter,Kevin Shieh,Misako Nagasaka et al.
Zhaohui Liao Arter et al.
Background: BRAF mutations are generally divided into three classes based on the different altered mechanism of activation. Methods: We...
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival [0.03%]
广泛期小细胞肺癌患者的基因组特征分析鉴别出与生存相关的分子因素
Matteo Canale,Milena Urbini,Elisabetta Petracci et al.
Matteo Canale et al.
Objective: Extensive stage Small-Cell Lung Cancer (ES-SCLC) is the most lethal lung cancer, and the addition of immunotherapy conferred a slight survival benefit for patients. Extensive molecular profiling of patients tre...
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC [0.03%]
KRAS G12C抑制剂adagrasib在KRYSATAL-12研究中未能打破NSCLC未言明的6个月PFS屏障谜题
Alexandria T M Lee,Misako Nagasaka
Alexandria T M Lee
Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated approval to adagrasib, a small molecule coval...
Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma [0.03%]
I期KRYSTAL-12试验破解了KRAS G12C密码子在非小细胞肺癌中的难题：Adagrasib显示强大而持久的疗效
Faustine X Luo,Zhaohui Liao Arter
Faustine X Luo
Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutant non-small cell lung carcinoma (NSCLC) accounts for approximately 10-13% of advanced nonsquamous NSCLC cases in Western populations, presenting a significant therapeutic challenge...
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea [0.03%]
韩国广泛期小细胞肺癌二线及后线卢比雷丁治疗的真实世界疗效分析
Joo Sung Shim,Youhyun Kim,Taeho Yuh et al.
Joo Sung Shim et al.
Purpose: Small-cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers and is characterized by a high recurrence rate, early metastasis, and poor prognosis. Before the FDA approved lurbinectedin for ...